Metastatic Castration-resistant Prostate Cancer
17 competing products in clinical development for Metastatic Castration-resistant Prostate Cancer.
Pipeline by Phase
Pre-clinical4
Phase 11
Phase 1/22
Phase 26
Phase 31
Approved3
All Products (17)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Enzalutamide | Astellas Pharma | Approved | Completed | 43 |
| Enzalutamide + Androgen deprivation therapy (ADT) | Astellas Pharma | Approved | Completed | 43 |
| ZEN003694 + Enzalutamide | Astellas Pharma | Phase 2 | Recruiting | 42 |
| Enzalutamide + Docetaxel + Prednisolone + Placebo | Astellas Pharma | Phase 3 | Completed | 40 |
| Enfortumab vedotin | Astellas Pharma | Phase 2 | Active | 39 |
| Valemetostat + Darolutamide | Daiichi Sankyo | Phase 1 | Recruiting | 36 |
| enzalutamide + abiraterone acetate + prednisone | Astellas Pharma | Phase 2 | Completed | 35 |
| Enzalutamide | Astellas Pharma | Approved | Terminated | 35 |
| Lu-PSMA + Enzalutamide | Astellas Pharma | Phase 2 | UNKNOWN | 31 |
| Enzalutamide | Astellas Pharma | Phase 2 | Withdrawn | 27 |
| Enzalutamide, 160mg, 40 mg soft capsules, once daily | Astellas Pharma | Pre-clinical | Completed | 26 |
| enzalutamide | Astellas Pharma | Pre-clinical | Completed | 26 |
| enzalutamide + docetaxel | Astellas Pharma | Pre-clinical | Completed | 26 |
| MDV3100 | Astellas Pharma | Pre-clinical | Completed | 26 |
| AZD5069 + Enzalutamide 40 MG | Astellas Pharma | Phase 1/2 | Terminated | 24 |
| Abiraterone Acetate + Tildrakizumab | Sun Pharmaceutical | Phase 1/2 | Terminated | 24 |
| SRF617 + etrumadenant + zimberelimab | Coherus BioSciences | Phase 2 | Terminated | 17 |